

Nevrargenics collaboration with King's College in Parkinson's

Date

June 2022

Nevrargenics Ltd, the UK biotech company focusing on developing novel small molecule drugs that modulate the retinoic acid receptors to treat neurodegenerative and other diseases, is pleased to announce an extension to our previously reported preliminary 6OH Parkinson's model study carried out in Professor Susan Duty's laboratories at King's College, London.

The preliminary, short study showed positive results with our lead drug, NVG0645, showing recovery of the lesion condition at a dose of 0.03 mg/kg. The new study we announce here will be an extension of this work, looking at longer term exposure, and dose genetic effects. This will further our understanding of our lead drug's potential for not only Parkinson's disease, but its mode of action and target engagement.

Notes

Parkinson's disease (PD) is characterised by motor symptoms which result from degeneration of dopaminergic neurons in the substantia nigra pars compacta. There are still no available treatments to protect against ongoing degeneration, or repair damage already present at diagnosis. The pathogenesis of PD is multi-factorial, supporting the need for novel drugs with multiple beneficial actions.

Growing evidence supports a functional role for retinoic acid (RA) signaling in neuronal survival, synaptic plasticity and neuronal repair, making this an attractive target for disease modification in PD. Recently, a group of novel retinoic acid receptor (RAR) modulators with dual genomic and cytoplasmic activity was generated by Nevrargenics' researchers.

For more information, contact:

Prof Andy Whiting, CEO
Nevrargenics Ltd
Ouse House
Mandale Park
Belmont Industrial Estate
Durham DH1 1TT
U.K.

info@nevrargenics.com

www.nevrargenics.com

Nevrargenics Ltd is a UK-based biotech company specialising in the discovery and development of novel medicines for the treatment of neurodegenerative disease, such as Alzheimer's, Parkinson's, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and other neurological and psychiatric diseases.